Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHVF)

254.50
Delayed Data
As of 2:38pm ET
 +0.76 / +0.30%
Today’s Change
216.45
Today|||52-Week Range
270.00
+11.65%
Year-to-Date
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
2:18pm / Zacks.com - Paid Partner Content
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
Mar 16 / Zacks.com - Paid Partner Content
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
12:10pm / Zacks.com - Paid Partner Content
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
Mar 15 / Zacks.com - Paid Partner Content
Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
6:52am / TheStreet.com - Paid Partner Content
How You Can Profit From the Next Big Thing in Healthcare
Mar 14 / MotleyFool.com - Paid Partner Content
Should Value Investors Pick Roche Holding (RHHBY)?
Mar 22 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close253.74
Today’s open253.25
Day’s range253.25 - 255.99
Volume329
Average volume (3 months)3,471
Market cap$178.3B
Dividend yield3.23%
Data as of 2:38pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)+5.53%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)+2.67%
P/E ratio--
Price/Sales3.83
Price/Book9.19

Competitors

No competitors data available.

Financials

Next reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$51.3B
Annual profit (last year)$9.7B
Net profit margin18.93%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Severin Schwan
Chief Financial &
Information Technology Officer
Alan Hippe
Corporate headquarters
Basel, Basel-stadt (basle Town)

Forecasts


Search for Jobs